← Back to Clinical Trials
Recruiting NCT06025149

NCT06025149 The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06025149
Status Recruiting
Phase
Sponsor Closed Joint-Stock Company NeoCor
Condition Aortic Valve Disease
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2018-09-01
Primary Completion 2025-09-09

Trial Parameters

Condition Aortic Valve Disease
Sponsor Closed Joint-Stock Company NeoCor
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2018-09-01
Completion 2025-09-09

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this open, prospective, multicenter study is analyze long-term outcomes of aortic/mitral valve replacement using the "UniLine" bioprosthesis in patients with acquired aortic or mitral valve diseases. Main research objectives: To analyze long-term (up to 12 years) outcome of aortic or mitral valve replacement using the "UniLine" bioprosthesis. To study the hemodynamic characteristics of normally functioning "UniLine " prostheses in the mitral or aortic valve position based on the transthoracic echocardiography data. To assess the number, type, time frames of dysfunctions of UniLine bioprostheses and the results of their treatment. To analyze the frequency of major serious adverse events associated with the "UniLine" bioprosthesis or procedure.

Eligibility Criteria

Inclusion Criteria: 1. Provided informed consent to participate in the study. 2. Must be aged 18 years and older. 3. Patients with isolated acquired mitral or aortic valve disease. 4. No prior heart valve replacement, current replacement must be planned (not conducted in an urgent/ emergency manner), using the "UniLine" biological prosthesis made from xenopericardium. 5. Patient must be able to visit the Research Center. Exclusion Criteria: 1. Mechanical or biological prosthesis in another position. Patients with tricuspid valve repair may be included in the study. 2. Prior heart valve replacement. 3. Concomitant interventions on the heart (coronary artery bypass grafting, coronary heart disease treatment, surgical reconstruction of a left ventricular aneurysm) and thoracic aorta. 4. Patients with cancer in history. 5. Patients with musculoskeletal conditions with severe movement disorders and diseases of the central nervous system, accompanied by cognitive disorders (disorientation, i

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology